2Xideas AG Trims Neurocrine Biosciences Stock Position

Hedge fund reduces stake in biotech company by 25.1% in Q3

Mar. 14, 2026 at 7:04am

Got story updates? Submit your updates here. ›

2Xideas AG, a hedge fund, trimmed its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 25.1% during the third quarter, according to a recent 13F filing with the SEC. The fund now owns 50,797 shares of the company's stock, down from 67,813 shares previously.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. The reduction in 2Xideas AG's position could signal a shift in investor sentiment around the company's prospects or valuation.

The details

According to the 13F filing, 2Xideas AG sold 17,016 shares of Neurocrine Biosciences during the third quarter. The hedge fund now owns about 0.05% of the company's outstanding shares, worth approximately $7.1 million as of the most recent filing.

  • 2Xideas AG filed its 13F report for the third quarter on March 14, 2026.

The players

2Xideas AG

A hedge fund that has invested in Neurocrine Biosciences.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders.

Got photos? Submit your photos here. ›

The takeaway

The reduction in 2Xideas AG's position in Neurocrine Biosciences could signal a shift in investor sentiment around the company's prospects or valuation, though the reasons behind the hedge fund's decision are not entirely clear from the available information.